Categories: News

Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13

DALLAS, Nov. 06, 2024 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2024, and host a corporate update conference call and webcast on Wednesday, November 13, 2024, at 4:30 PM Eastern Time.

Conference Call Details
Wednesday, November 13, at 4:30 PM Eastern Time / 3:30 PM Central Time
Toll Free: 877-407-0792
International: 201-689-8263
Conference ID: 13748703
Webcast: https://ir.tayshagtx.com/news-events/events-presentations

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.

Company Contact:
Hayleigh Collins
Director, Head of Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com

Media Contact:
Carolyn Hawley
Inizio Evoke
carolyn.hawley@inizioevoke.com

Staff

Recent Posts

Hear at Last Signs a Canada Wide Distribution with Hohm Pods for Portable Home Pods

Toronto, Ontario--(Newsfile Corp. - November 7, 2024) - HearAtLast Holdings, Inc. (OTC Pink: HRAL), is…

31 mins ago

Vitaquest Hires David Alcaraz as Senior Vice President, Quality Assurance

Alcaraz brings nearly 20 years of experience in quality management to the roleWest Caldwell, New…

1 hour ago

BioHarvest Sciences Announces Uplisting to the Nasdaq Global Market

Common Shares to Begin Trading on Nasdaq on Tuesday, November 12, 2024Vancouver, British Columbia and…

1 hour ago

NervGen Pharma to Present at the Stifel 2024 Healthcare Conference

Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB:…

1 hour ago

Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update

Halifax, Nova Scotia--(Newsfile Corp. - November 7, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB:…

1 hour ago

Ludwig Enterprises Begins PCR Validation Test Process

Final step before the full launch of breast cancer screening program, Revealia™SPARKS, NV / ACCESSWIRE…

1 hour ago